CytoDyn (STU:296) Total Stockholders Equity: €-93.92 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
31 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is CytoDyn Total Stockholders Equity?

CytoDyn STU:296 -2.04% 31 Total Stockholders Equity is €-93.92 Mil as of May. 2026. GuruFocus rates STU:296 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

CytoDyn's Total Stockholders Equity for the quarter that ended in May. 2026 was €-93.92 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CytoDyn's Book Value per Share for the quarter that ended in May. 2026 was €-0.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CytoDyn's Debt-to-Equity for the quarter that ended in May. 2026 was -0.25.

CytoDyn  (STU:296) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CytoDyn's Book Value per Share for the quarter that ended in May. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-93.919-0)/1373.517
=-0.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CytoDyn's Debt-to-Equity for the quarter that ended in May. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.756 + 22.592) / -93.919
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Stockholders Equity Related Terms

CytoDyn Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CytoDyn's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Stockholders Equity Chart

CytoDyn Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -89.30 -100.74 -108.00 -85.19 -93.92

CytoDyn Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.19 -85.48 -103.58 -88.23 -93.92
STU:296
31GF Score
CytoDyn Inc STU:296
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €-93.92 Mil mean?
CytoDyn (STU:296) has a Total Stockholders Equity of €-93.92 Mil as of May. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors.
Is CytoDyn's Total Stockholders Equity too high?
CytoDyn's current Total Stockholders Equity is €-93.92 Mil. Overall, CytoDyn has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Total Stockholders Equity compare to OBIO and IRD?
CytoDyn's Total Stockholders Equity of €-93.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors. CytoDyn's current Total Stockholders Equity is €-93.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Total Stockholders Equity of €-93.92 Mil. The current Total Stockholders Equity is €-93.92 Mil. CytoDyn's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For CytoDyn (STU:296), the current Total Stockholders Equity is €-93.92 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
31GF Score

Get the complete analysis for STU:296

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price